Elsevier

The Journal of Pediatrics

Volume 170, March 2016, Pages 20-27
The Journal of Pediatrics

Medical Progress
Treatment Options for Type 2 Diabetes in Youth Remain Limited

https://doi.org/10.1016/j.jpeds.2015.11.015Get rights and content

Section snippets

Methods

A literature search was conducted using PubMed with librarian assistance. We included systematic reviews4, 16, 17, 18, 19, 20, 21 as well as retrospective and randomized prospective trials of medications and bariatric surgery that were limited to persons under the age of 18 years with T2D. Only research from the past 10 years was considered. We also reviewed ClinicalTrials.gov looking at active trials using the search terms “type 2 diabetes children” and “type 2 diabetes pediatrics.”

Discussion

Only 2 medications are FDA-approved for the treatment of youth with T2D: metformin and insulin. Recruitment of children and adolescents with T2D for clinical trials is limited as many clinical trials are looking for subjects who are between 10 and 17 years of age and have not been started on insulin therapy, an exclusion criterion for almost all of the T2D clinical trials. A recent commentary in Diabetes Care recommended that the age range of availability be increased from 10-17 years to

First page preview

First page preview
Click to open first page preview

References (62)

  • H.A. Tindle et al.

    Risk of suicide after long-term follow-up from bariatric surgery

    Am J Med

    (2010)
  • G. Imperatore et al.

    Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth

    Diabetes Care

    (2012)
  • D. Dabelea et al.

    Incidence of diabetes in youth in the United States

    JAMA

    (2007)
  • Type 2 diabetes in children and adolescents

    Diabetes Care

    (2000)
  • F. Bacha et al.

    Progressive deterioration of β-cell function in obese youth with type 2 diabetes

    Pediatr Diabetes

    (2013)
  • S.E. Kahn

    Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes

    J Clin Endocrinol Metab

    (2001)
  • W.C. Knowler et al.

    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

    N Engl J Med

    (2002)
  • W.C. Knowler et al.

    Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

    Lancet

    (2009)
  • P. Zeitler et al.

    A clinical trial to maintain glycemic control in youth with type 2 diabetes

    N Engl J Med

    (2012)
  • C.D.C. Prevention

    National Diabetes Statistics Report: Estimates of diabetes and its burden in the United States, 2014

    (2014)
  • S.A. Mulvaney et al.

    Self-management in type 2 diabetes: the adolescent perspective

    Diabetes Educ

    (2008)
  • S.C. Springer et al.

    Management of type 2 diabetes mellitus in children and adolescents

    Pediatrics

    (2013)
  • S.T. Johnson et al.

    In search of quality evidence for lifestyle management and glycemic control in children and adolescents with type 2 diabetes: a systematic review

    BMC Pediatr

    (2010)
  • M.M. George et al.

    Current treatment options for type 2 diabetes mellitus in youth: today's realities and lessons from the TODAY study

    Curr Diab Rep

    (2013)
  • P. Zeitler et al.

    ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent

    Pediatr Diabetes

    (2014)
  • Standards of medical care in diabetes—2014

    Diabetes Care

    (2014)
  • R.S. Hundal et al.

    Mechanism by which metformin reduces glucose production in type 2 diabetes

    Diabetes

    (2000)
  • E. Ferrannini

    The target of metformin in type 2 diabetes

    N Engl J Med

    (2014)
  • J.B. Buse et al.

    The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies

    Diabetes Care

    (2015)
  • M. Freemark et al.

    The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

    Pediatrics

    (2001)
  • S.E. Inzucchi et al.

    Metformin in patients with type 2 diabetes and kidney disease: a systematic review

    JAMA

    (2014)
  • Cited by (6)

    • The increasing trend of Type 2 diabetes in youth: An overview

      2021, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
      Citation Excerpt :

      This, combined with the more aggressive progression of T2DM in children renders these adjustments ineffective as monotherapy to treat youth with T2DM [26]. The pharmacological treatment of youth T2DM patients focuses on controlling insulin resistance, one of the major mechanisms of T2DM [29]. Metformin is the drug of choice for youth T2DM patients, and is the only FDA approved treatment option beyond lifestyle therapy and insulin itself [25,30].

    • Interleukin-38 increases the insulin sensitivity in children with the type 2 diabetes

      2020, International Immunopharmacology
      Citation Excerpt :

      The pathophysiological mechanisms underlying pediatric T2DM remain largely unknown. However, insulin resistance (IR) and inflammation are two the major contributors for T2DM development [14,19–27]. However, whether these two factors are interacted with each other remains unclear in pediatric T2DM.

    • A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data

      2017, Journal of Diabetes and its Complications
      Citation Excerpt :

      Moreover, even when adolescents with T2DM achieve control with the combination of metformin and insulin, many fail to maintain adequate control after several months of treatment. These outcomes indicate a more aggressive course of T2DM in adolescents compared to adults with T2DM, and therefore an urgent need to optimize therapeutic options for pediatric T2DM.16,17 Several ongoing clinical trials in pediatric patients with T2DM should provide useful safety information upon conclusion.16,17

    • Health care, insurance, and school policy affecting diabetes in the pediatric population

      2020, Behavioral Diabetes: Social Ecological Perspectives for Pediatric and Adult Populations

    J.S. is conducting clinical trials for Daichi Sankyo and Boehringer Ingelheim; and serves as an Editorial Board member for The Journal of Pediatrics. C.M. declares no conflicts of interest.

    View full text